Development and Validation of a Novel Nomogram Model for Predicting the Survival of Patients with T2-4a, N0-x, M0 Bladder Cancer: a Retrospective Cohort Study

Overview

Journal Am J Clin Exp Urol

Specialty Urology

Date 2023 Dec 27

PMID 38148935

Authors

Yu Xia

Xi Liu

Binbin Ma

Tao Huang

Danfeng Xu

Chenhui Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: Recent developments in bladder cancer treatment strategies have significantly improved the prognosis of clinically curable muscle invasive bladder cancer (MIBC) patients. Here, the prognostic factors of T2-4a, N0-x, M0 MIBC patients were investigated using the Surveillance, Epidemiology, and End Results (SEER) database and a novel nomogram model was established for prognosis prediction.

Methods: The data of 7,292 patients with T2-4a, N0-x, M0 MIBC were retrieved from the SEER database (2000-2020) and randomly classified into a training set (n = 5,106) and validation set (n = 2,188). Kaplan-Meier analysis was used to calculate cancer-specific survival (CSS) and overall survival (OS) rates of patients, and differences between survival curves were analyzed using the log-rank test. Cox regression analysis was used to screen and incorporate patient prognosis-affecting independent risk factors into the nomogram model. Consistency index (C-index) values and areas under the time-dependent receiver operating characteristic curve (AUC) were used to evaluate the discriminatory ability, and the calibration curve was used to assess the calibration of the model. Its predictive performance and American Joint Committee on Cancer (AJCC) stage were compared using decision curve analysis (DCA).

Results: The 1-, 3-, and 5-year CSS and OS rates of patients with T2-4a, N0-x, M0 MIBC were 76.9%, 56.0%, and 49.9%, respectively, and 71.3%, 47.9%, and 39.5%, respectively. Cox regression analysis showed that age, marital status, race, pathological type, tumor size, AJCC stage, T stage, N stage, surgery of primary tumor, regional lymph node dissection, radiation, and chemotherapy were independent prognostic risk factors of both CSS and OS (P < 0.05). The C-index and AUC of the nomogram model constructed based on the training and validation sets were both > 0.7, and calibration curves for predicting the 1-, 3-, and 5-year survival were consistent with the ideal curve. The nomogram model showed a higher net benefit with DCA than AJCC stage analysis.

Conclusion: The nomogram model could accurately predict the prognosis of patients with T2-4a, N0-x, M0 MIBC. It may help clinicians perform personalized prognosis evaluations and formulate treatment plans.

References

Diamantopoulos L, Makrakis D, Korentzelos D, Alevizakos M, Wright J, Grivas P . Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma. Urol Oncol. 2023; 41(6):296.e17-296.e28. DOI: 10.1016/j.urolonc.2023.01.019. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Wen P, Wen J, Huang X, Wang F . Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program. J Clin Med. 2023; 12(4). PMC: 9962885. DOI: 10.3390/jcm12041314. View

Wang S, Ge C, Zhang J . Incidence, prognostic factors and survival in bladder cancer patients: a population-based study. Transl Cancer Res. 2022; 11(8):2742-2756. PMC: 9459577. DOI: 10.21037/tcr-22-46. View

Audenet F, Waingankar N, Ferket B, Niglio S, Marqueen K, Sfakianos J . Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. J Urol. 2018; 200(5):996-1004. DOI: 10.1016/j.juro.2018.06.001. View

Wang J, Wu Y, He W, Yang B, Gou X . Nomogram for predicting overall survival of patients with bladder cancer: A population-based study. Int J Biol Markers. 2020; 35(2):29-39. DOI: 10.1177/1724600820907605. View

Fonteyne V, Ost P, Bellmunt J, Droz J, Mongiat-Artus P, Inman B . Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol. 2017; 73(1):40-50. DOI: 10.1016/j.eururo.2017.03.019. View

Stenzl A, Cowan N, De Santis M, Jakse G, Kuczyk M, Merseburger A . The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55(4):815-25. DOI: 10.1016/j.eururo.2009.01.002. View

Krajewski W, Faba O, Breda A, Pisano F, Poletajew S, Tukiendorf A . Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer. World J Urol. 2020; 38(12):3177-3182. DOI: 10.1007/s00345-020-03130-1. View

10.

Tao L, Pan X, Zhang L, Wang J, Zhang Z, Zhang L . Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study. Front Oncol. 2020; 10:586458. PMC: 7654226. DOI: 10.3389/fonc.2020.586458. View

11.

Zhan X, Jiang M, Deng W, Liu X, Chen L, Fu B . Development and Validation of a Prognostic Nomogram for Predicting Cancer-Specific Survival in Patients With Lymph Node Positive Bladder Cancer: A Study Based on SEER Database. Front Oncol. 2022; 12:789028. PMC: 8851926. DOI: 10.3389/fonc.2022.789028. View

12.

Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M . Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(3):329-354. DOI: 10.6004/jnccn.2020.0011. View

13.

Mason S, Downing A, Wright P, Hounsome L, Bottomley S, Corner J . Health-related quality of life after treatment for bladder cancer in England. Br J Cancer. 2018; 118(11):1518-1528. PMC: 5988662. DOI: 10.1038/s41416-018-0084-z. View

14.

Liu L, Li C, Wang Q, Yuan H, Wang Y . A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study. Eur J Med Res. 2023; 28(1):61. PMC: 9893594. DOI: 10.1186/s40001-022-00970-y. View

15.

Wang Y, Chang Q, Li Y . Racial differences in Urinary Bladder Cancer in the United States. Sci Rep. 2018; 8(1):12521. PMC: 6104025. DOI: 10.1038/s41598-018-29987-2. View

16.

Milowsky M, Rumble R, Booth C, Gilligan T, Eapen L, Hauke R . Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016; 34(16):1945-52. DOI: 10.1200/JCO.2015.65.9797. View

17.

Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C . Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol. 2016; 34(8):825-32. DOI: 10.1200/JCO.2015.64.1076. View

18.

Fang W, Yang Z, Chen T, Shen X, Zhang C . Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020; 18(1):145. PMC: 7106682. DOI: 10.1186/s12967-020-02308-w. View

19.

El-Achkar A, Souhami L, Kassouf W . Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. Curr Urol Rep. 2018; 19(12):108. DOI: 10.1007/s11934-018-0859-z. View

20.

Abdel-Rahman O . Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis. Clin Genitourin Cancer. 2016; 15(3):e463-e468. DOI: 10.1016/j.clgc.2016.10.007. View